Work

In vivo selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing E. coli ST410

Year: 2026

Type: article

Abstract: ABSTRACT Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing Escherichia coli ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01335-25

Authors: Agnès B. Jousset, Delphine Girlich, Saoussen Oueslati, Aurélien Birer, Anne Delaval, Caroline Guyot, Ines Rezzoug, Cécile Emeraud, Thierry Naas, Rémy A. Bonnin, Laurent Dortet

Institutions: Inserm, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, CEA Paris-Saclay, Infectious Disease Models and Innovative Therapies, CNR de la Résistance aux Antibiotiques, Bicêtre Hospital, Groupe Hospitalier Intercommunal Le Raincy Montfermeil

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Agence Nationale de la Recherche

Award: aPpROche par Médecine de prEcision pour la prise en charge THérapeutique du sEpsis commUnautaire et lié aux Soins

OpenAlex ID: W7128692282

FWCI: 3.968

Cites: 24

Cited by: 2

Related to: